Soleil Boughton Sells 2,343 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,343 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the completion of the transaction, the insider now owns 165,254 shares in the company, valued at $4,941,094.60. This represents a 1.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.16, for a total value of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.41, for a total transaction of $47,738.99.
• On Tuesday, September 17th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50.
• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $0.69 during trading hours on Tuesday, hitting $30.67. The stock had a trading volume of 19,581,394 shares, compared to its average volume of 9,741,340. The firm has a market capitalization of $6.70 billion, a price-to-earnings ratio of 69.73 and a beta of 1.06. Hims & Hers Health, Inc. has a one year low of $8.09 and a one year high of $31.68. The company has a 50 day simple moving average of $20.85 and a two-hundred day simple moving average of $19.44.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the business earned ($0.04) earnings per share. Hims & Hers Health’s revenue for the quarter was up 77.1% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on HIMS shares. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price target for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Finally, Piper Sandler reissued a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $20.71.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of the company. Quest Partners LLC grew its holdings in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the last quarter. CWM LLC raised its stake in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Hims & Hers Health by 3.0% during the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after purchasing an additional 1,173 shares during the period. Victory Capital Management Inc. grew its stake in shares of Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after purchasing an additional 1,212 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.